Raleigh, North Carolina –The National Institute of General Medical Science (NIGMS) at the National Institutes of Health (NIH) has awarded an Alzheimer’s Supplement grant while the National Center for Complementary and Integrative Health at the NIH has awarded a Phase I SBIR to Collaborations Pharmaceuticals, Inc. (CPI) to develop software in order to find new uses for natural products using a large collection of machine learning models.
“These grants will demonstrate how we can apply a wide array of machine learning approaches to discovering small molecules for an array of targets for Alzheimer’s disease as well as finding additional uses for the many natural products that are already available and constantly being optimized in academic labs. These grants will serve to further validate our strategy for combining computational and in vitro approaches” said Sean Ekins, PhD, chief executive officer of CPI.”
“We are very grateful to NIH-NIGMS and NIH- NCCIH for their support and providing this opportunity to potentially develop new collaborations in these research areas. Alzheimer’s Disease is widely known as the most common type of dementia, it is an irreversible neurodegenerative disease that is also the 6th leading cause of death in USA, affecting over 5.1 million adults over age 65, and costs over $150 billion per year. Clearly there is considerable data for various targets for this disease and to date there has been little in the way of success. We aim to try to change this. In addition, our new Phase I SBIR will enable us to develop software to provide predictions for a natural product (or any molecule) and identify targets for efficacy assessment as well as identify any potential liabilities. We will validate these predictions in vitro as well.To date there has been relatively limited prediction of natural products and drug-target interactions so this represents a valuable opportunity to develop machine learning models with different methods and apply them to published and collaborator’s molecules to identify new uses.” Ekins said.
About Collaborations Pharmaceuticals, Inc.
Collaborations Pharmaceuticals, Inc. performs research and development on innovative therapeutics for multiple rare and infectious diseases. We partner with academics or companies to identify and translate early preclinical to clinical stage assets. We have considerable experience of preclinical and computational approaches to drug discovery and toxicity prediction. We apply our various software tools for data curation and machine learning as represented by Assay Central (www.assaycentral.org).
For more information, please visit http://www.collaborationspharma.com/
Contact information CPI
Sean Ekins, Ph.D., D.Sc.
CEO and Founder,
Collaborations Pharmaceuticals, Inc.
840 Main Campus Drive, Lab 3510,
Raleigh, NC 27606